Abstract
The assessment of S-100B in acute neurological disorders such as global hypoxia, ischaemic or haemorrhagic stroke and traumatic brain injury reflects severity of symptoms and outcome. However, the temporal profile of S-100B release depends on topography, intensity and pathophysiology of the damage e.g. immediate release after traumatic brain injury following the acute destruction of neuronal tissue or delayed release after ischaemic stroke in which gradual breakdown of the blood-brain barrier plays a crucial role. In chronic brain diseases, knowledge about the clinical value of quantification of S-100B is scarce and further evaluations are needed. This review considers both conditions for S-100B measurement and illustrates advantages and limitations in comparison with clinical and neuroimaging data.
Keywords: S-100B, stroke, global hypoxia, traumatic brain injury
Current Medicinal Chemistry
Title: Protein S-100B - A Prognostic Marker for Cerebral Damage
Volume: 13 Issue: 25
Keywords: S-100B, stroke, global hypoxia, traumatic brain injury
Abstract: The assessment of S-100B in acute neurological disorders such as global hypoxia, ischaemic or haemorrhagic stroke and traumatic brain injury reflects severity of symptoms and outcome. However, the temporal profile of S-100B release depends on topography, intensity and pathophysiology of the damage e.g. immediate release after traumatic brain injury following the acute destruction of neuronal tissue or delayed release after ischaemic stroke in which gradual breakdown of the blood-brain barrier plays a crucial role. In chronic brain diseases, knowledge about the clinical value of quantification of S-100B is scarce and further evaluations are needed. This review considers both conditions for S-100B measurement and illustrates advantages and limitations in comparison with clinical and neuroimaging data.
Export Options
About this article
Cite this article as:
Protein S-100B - A Prognostic Marker for Cerebral Damage, Current Medicinal Chemistry 2006; 13 (25) . https://dx.doi.org/10.2174/092986706778521751
DOI https://dx.doi.org/10.2174/092986706778521751 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Effects of the Novel Non-Peptidyl Low Molecular Weight Radical Scavenger IAC in Different Models of Inflammation: A New Perspective in Anti-Inflammatory Therapy
Current Medicinal Chemistry The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children
Current Drug Metabolism Relevance of Pharmacokinetics and Bioavailability of Intranasal Corticosteroids in Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery The Mechanism of Adjuvanticity of Aluminium-Containing Formulas
Current Pharmaceutical Design Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Dexamethasone Use During Pregnancy: Potential Adverse Effects on Embryonic Skeletogenesis
Current Pharmaceutical Design Gut Microbiota of Obese, Type 2 Diabetic Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier
Current Drug Metabolism Getting to Know the Cast - Cellular Interactions and Signaling at the Neurovascular Unit
Current Pharmaceutical Design CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics The Role of Colchicine in the Prevention of Cerebrovascular Ischemia
Current Pharmaceutical Design Globalization of Clinical Trials – Where are We Heading?
Current Clinical Pharmacology Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets